THERAPEUTICS
Antihypertensive therapy with indapamide and perindopril reduced mortality in patients
80 years
| The first 150 words of the full text of this article appear below. |
N S Beckett
Dr N S Beckett, Imperial College, London, UK; n.beckett@imperial.ac.uk
STUDY DESIGN
randomised placebo controlled trial (Hypertension in the Very Elderly Trial [HYVET]).
{concealed}*.
blinded (patients, clinicians, and outcome adjudication committee).
STUDY QUESTION
195 centres in Europe, China, Australasia, and Tunisia.
3845 patients
80 years of age (mean age 84 y, 60% women) with persistent hypertension (mean sitting blood pressure [BP] 173/91 mm Hg). Exclusion criteria included accelerated or secondary hypertension, haemorrhagic stroke in the past 6 months, heart failure, gout, and dementia.
sustained-release indapamide, 1.5 mg/day, with perindopril, 2 or 4 mg/day, added if needed to reach targets of systolic BP <150 mm Hg and diastolic BP <80 mm Hg (n = 1933) or placebo (n = 1912).
stroke, heart failure, any cardiovascular event, and death from any cause, cardiovascular cause, cardiac cause, or stroke.
median 1.8 years.
99.6% (intention-to-treat analysis).
MAIN RESULTS
Antihypertensive treatment reduced risks of heart failure, any cardiovascular event,
Mount Sinai Medical Center, New York, New York, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
